https://m2.mtmt.hu/ hun 2026-05-26 01:49 JournalArticle 34830527 VALIDATED true Funding Agency and Grant Number: Semmelweis Science and Innovation Fund; New National Excellence Program of the Ministry for Culture and Innovation from National Research, Development and Innovation Fund [UNKP-23-3-II-SE- 95, UNKP-23-3-II-BME-88]; National Research, Development and Innovation Office, Hungary [TKP2021- NVA-14, NKFIH FK 146930, NKFI-K-142799] Funding text: This research was funded by the Semmelweis Science and Innovation Fund [I.S.: STIA-KFI 2022], by the New National Excellence Program of the Ministry for Culture and Innovation from the Source of the National Research, Development and Innovation Fund [B.M.B.: UNKP-23-3-II-SE- 95 and Sz.K.: UNKP-23-3-II-BME-88] and supported by the National Research, Development and Innovation Office, Hungary [B.F.: TKP2021- NVA-14; G.T.: NKFIH FK 146930; A.S.: NKFI-K-142799]. 0 false 2026-05-23T19:03:27.280+0000 2026-02-11T11:07:40.967+0000 2024-05-01T21:09:52.979+0000 true 10015206 Áncsán Gizella /api/admin/10015206 Admin Áncsán Gizella (SE admin) true 10015206 2026-02-17T10:07:30.193+0000 2025-04-25T15:05:47.275+0000 true 10072107 Asztalos Annamária /api/admin/10072107 Admin Asztalos Annamária (KMF admin4) true 2025-04-25T15:05:54.301+0000 true 10072107 Asztalos Annamária /api/admin/10072107 Admin Asztalos Annamária (KMF admin4) true true false true 24 24 /api/publicationtype/24 PublicationType Folyóiratcikk 1 true 24 JournalArticle true 10000059 Article true 24 24 /api/publicationtype/24 PublicationType Folyóiratcikk 1 true 24 JournalArticle /api/subtype/10000059 Szakcikk SubType Szakcikk (Folyóiratcikk) 101 true 10000059 true 1 /api/category/1 Category Tudományos true 1 Benkő, Beáta-Mária true true /api/journal/2083 REVIEWED INTERNATIONAL JOURNAL OF PHARMACEUTICS 0378-5173 1873-3476 true false 2083 false 2083 true 0378-5173 1873-3476 Journal FOREIGN 657 124187 124187 14 2024 Funding 2050239 /api/funding/2050239 (STIA-KFI-2022) false true Funding 2050240 /api/funding/2050240 Új Nemzeti Kiválóság Program(ÚNKP-23-3-II-SE95) Támogató: Nemzeti Kutatás, Fejlesztés és Innovációs Iroda false true Funding 2050241 /api/funding/2050241 Új Nemzeti Kiválóság Program(ÚNKP-23-3-II-BME-88) Támogató: Nemzeti Kutatás, Fejlesztés és Innovációs Iroda false true Funding 2050242 /api/funding/2050242 (TKP2021-NVA-14) Támogató: NKFIH false true Funding 2050243 /api/funding/2050243 (NKFIH FK 146930) Támogató: NKFIH false true Funding 2050244 /api/funding/2050244 (NKFI-K-142799) Támogató: NKFI false true true true 2024 true true true false true false GOLD 2026-05-23 true https://doi.org/10.1016/j.ijpharm.2024.124187 17 0 16 13 3 16 16 15 15 16 16 13 13 14 3 0 17 14 16 13 0 11 11 Folyóiratcikk Journal Article 24 16 Könyvrészlet Chapter in Book 25 0 Könyv Book 23 0 Egyéb konferenciaközlemény Conference paper 31 0 Egyéb konferenciakötet Conference proceedings 32 0 Oltalmi formák Protection forms 26 0 Disszertáció Thesis 28 1 Egyéb Miscellaneous 29 0 Alkotás Achievement 22 0 Kutatási adat Research data 33 0 Folyóiratcikk Journal Article 24 0 0 0 Könyvrészlet Chapter in Book 25 0 0 0 Könyv Book 23 0 0 0 Egyéb konferenciaközlemény Conference paper 31 0 0 0 Egyéb konferenciakötet Conference proceedings 32 0 0 0 Oltalmi formák Protection forms 26 0 0 0 Disszertáció Thesis 28 0 0 0 Egyéb Miscellaneous 29 0 0 0 Alkotás Achievement 22 0 0 0 Kutatási adat Research data 33 0 0 0 2024 0 2 2 2 2 2025 0 10 9 10 9 2026 0 5 3 5 3 Q1 false 10062688,10002587 false false false 2024-05-13T06:58:43.985+0000 Biológia és Kémia Tanszék (RE); CycloLab Cyclodextrin Research and Development ...; Egis Gyógyszergyár Zrt.; Egyetemi Gyógyszertár Gyógyszerügyi Szervezési ... (SE / GYTK); Gyógyszerészi Kémiai Intézet (SE / GYTK); Kémiai Intézet (ME / AVK); Patológiai és Kísérleti Rákkutató Intézet (SE / AOK / I); Szerves Kémia és Technológia Tanszék (BME / VBK) 11 45 8 12 0 true Language 10002 /api/language/10002 Angol Angol English true 2 true PersonAuthorship 116454646 /api/authorship/116454646 Benkő, Beáta-Mária [Benkő, Beáta Mária (Gyógyszerészet), szerző] Egyetemi Gyógyszertár Gyógyszerügyi Szervezési ... (SE / GYTK) 1 0.083 true false false Author 10080598 /api/author/10080598 Benkő Beáta Mária (Gyógyszerészet) Benkő Beáta Mária true true Benkő Beáta-Mária true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 116454647 /api/authorship/116454647 Tóth, Gergő [Tóth, Gergő (gyógyszerkémia/an...), szerző] Gyógyszerészi Kémiai Intézet (SE / GYTK) 2 0.083 false false false Author 10028950 /api/author/10028950 Tóth Gergő (gyógyszerkémia/analitika) Tóth Gergő true 10028950 true Tóth Gergő true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 116454648 /api/authorship/116454648 Moldvai, Dorottya [Moldvai, Dorottya (Tumorbiológia), szerző] Patológiai és Kísérleti Rákkutató Intézet (SE / AOK / I) 3 0.083 false false false Author 10078438 /api/author/10078438 Moldvai Dorottya (Tumorbiológia) Moldvai Dorottya true true Moldvai Dorottya true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 116454649 /api/authorship/116454649 Kádár, Szabina [Kádár, Szabina (Gyógyszertechnológia), szerző] Gyógyszerészi Kémiai Intézet (SE / GYTK); Szerves Kémia és Technológia Tanszék (BME / VBK) 4 0.083 false false false Author 10073811 /api/author/10073811 Kádár Szabina (Gyógyszertechnológia) Kádár Szabina true true Kádár Szabina true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 116454650 /api/authorship/116454650 Szabó, Edina [Szabó, Edina (Gyógyszertechnológia), szerző] Szerves Kémia és Technológia Tanszék (BME / VBK) 5 0.083 false false false Author 10062688 /api/author/10062688 Szabó Edina (Gyógyszertechnológia) Szabó Edina true 10062688 true Szabó Edina true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 116454651 /api/authorship/116454651 Szabó, Zoltán-István 6 0.083333336 false false false Szabó Zoltán-István true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 116454652 /api/authorship/116454652 Kraszni, Márta [Mazákné Kraszni, Márta (Analitikai kémia,...), szerző] Gyógyszerészi Kémiai Intézet (SE / GYTK) 7 0.083 false false false Author 10012052 /api/author/10012052 Mazákné Kraszni Márta (Analitikai kémia, gyógyszerkémia) Mazákné Kraszni Márta true 10012052 true Kraszni Márta true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 116454653 /api/authorship/116454653 Szente, Lajos [Szente, Lajos (Szerves kémia), szerző] CycloLab Cyclodextrin Research and Development ... 8 0.083333336 false false false Author 10008597 /api/author/10008597 Szente Lajos (Szerves kémia) Szente Lajos true 10008597 true Szente Lajos true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 116454654 /api/authorship/116454654 Fiser, Béla [Fiser, Béla (Számítógépes kémi...), szerző] Kémiai Intézet (ME / AVK); Biológia és Kémia Tanszék (RE) 9 0.083 false false false Author 10040691 /api/author/10040691 Fiser Béla (Számítógépes kémia, Anyagtudomány) Fiser Béla true 10040691 true Fiser Béla true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 116454655 /api/authorship/116454655 Sebestyén, Anna [Sebestyén, Anna (Tumorbiológia), szerző] Patológiai és Kísérleti Rákkutató Intézet (SE / AOK / I) 10 0.083 false false false Author 10000745 /api/author/10000745 Sebestyén Anna (Tumorbiológia) Sebestyén Anna true 10000745 true Sebestyén Anna true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 116454656 /api/authorship/116454656 Zelkó, Romána ✉ [Zelkó, Romána (Gyógyszertechnológia), szerző] Egyetemi Gyógyszertár Gyógyszerügyi Szervezési ... (SE / GYTK) 11 0.083 false false true Author 10002587 /api/author/10002587 Zelkó Romána (Gyógyszertechnológia) Zelkó Romána true 10002587 true Zelkó Romána true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 116454657 /api/authorship/116454657 Sebe, István [Sebe, István (Gyógyszertechnológia), szerző] Egyetemi Gyógyszertár Gyógyszerügyi Szervezési ... (SE / GYTK); Egis Gyógyszergyár Zrt. 12 0.083 false true Author 10035401 /api/author/10035401 Sebe István (Gyógyszertechnológia) Sebe István true 10035401 true Sebe István true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PublicationIdentifier 26119102 /api/publicationidentifier/26119102 DOI: 10.1016/j.ijpharm.2024.124187 PlainSource 6 /api/publicationsource/6 DOI PublicationSourceType 10001 /api/publicationsourcetype/10001 DOI true true true DOI DOI https://doi.org/@@@ true true 6 true GOLD true IDENTICAL 10.1016/j.ijpharm.2024.124187 https://doi.org/10.1016/j.ijpharm.2024.124187 false true PublicationIdentifier 26547793 /api/publicationidentifier/26547793 WoS: 001239063800001 PlainSource 1 /api/publicationsource/1 WoS PublicationSourceType 10003 /api/publicationsourcetype/10003 Indexelő adatbázis false true true WoS WoS https://www.webofscience.com/wos/woscc/full-record/@@@ true true 1 true IDENTICAL 001239063800001 https://www.webofscience.com/wos/woscc/full-record/001239063800001 false true PublicationIdentifier 27380814 /api/publicationidentifier/27380814 REAL: 205320 SwordSource 36 /api/publicationsource/36 REAL PublicationSourceType 10007 /api/publicationsourcetype/10007 Repozitórium true true true REAL REAL http://real.mtak.hu/@@@ true true 36 true GOLD true 205320 http://real.mtak.hu/205320 false true PublicationIdentifier 26161721 /api/publicationidentifier/26161721 Scopus: 85192089867 PlainSource 3 /api/publicationsource/3 Scopus PublicationSourceType 10003 /api/publicationsourcetype/10003 Indexelő adatbázis false true true Scopus Scopus http://www.scopus.com/record/display.url?origin=inward&eid=2-s2.0-@@@ true true 3 true IDENTICAL 85192089867 http://www.scopus.com/record/display.url?origin=inward&eid=2-s2.0-85192089867 false true PublicationIdentifier 26175932 /api/publicationidentifier/26175932 PubMed: 38697585 PlainSource 17 /api/publicationsource/17 PubMed PublicationSourceType 10003 /api/publicationsourcetype/10003 Indexelő adatbázis false true true PubMed PubMed http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=@@@&dopt=Abstract true true 17 true IDENTICAL 38697585 http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=38697585&dopt=Abstract false true SjrRating 11491039 /api/sjrrating/11491039 sjr:Q1 (2024) Scopus - Pharmaceutical Science INTERNATIONAL JOURNAL OF PHARMACEUTICS 0378-5173 1873-3476 26 0.24 journal RatingType 10002 /api/ratingtype/10002 sjr sjr true true ClassificationExternal 3003 /api/classificationexternal/3003 Scopus - Pharmaceutical Science true 3003 true Q1 DIRECT true true Reference 52453180 /api/reference/52453180 1. Alifieris 2015: Glioblastoma multiforme: pathogenesis and treatment., Pharmacol. Ther., 152, p. 63, DOI: 10.1016/j.pharmthera.2015.05.005 1 10.1016/j.pharmthera.2015.05.005 false true Reference 52453181 /api/reference/52453181 2. Allensworth 2015: Disulfiram (DSF) acts as a copper ionophore to induce copper-dependent oxidative stress and mediate anti-tumor efficacy in inflammatory breast cancer., Mol. Oncol., 9, p. 1155, DOI: 10.1016/j.molonc.2015.02.007 2 10.1016/j.molonc.2015.02.007 false true Reference 52453182 /api/reference/52453182 3. Bartos 2021: Comparison of modern in vitro permeability methods with the aim of investigation nasal dosage forms., Pharmaceutics, 13, DOI: 10.3390/pharmaceutics13060846 3 10.3390/pharmaceutics13060846 false true Reference 52453183 /api/reference/52453183 4. Beneš 2012: Determination of stability constants of complexes of neutral analytes with charged cyclodextrins by affinity capillary electrophoresis., Electrophoresis, 33, p. 1032, DOI: 10.1002/elps.201100489 4 10.1002/elps.201100489 false true Reference 52453184 /api/reference/52453184 5. Benkő 2023: Clinical, pharmacological and formulation evaluation of disulfiram in the treatment of glioblastoma - a systematic literature review., Expert Opin. Drug Deliv., 20, p. 541, DOI: 10.1080/17425247.2023.2190581 5 10.1080/17425247.2023.2190581 false true Reference 52453185 /api/reference/52453185 6. Borbás 2019: Prediction of bioequivalence and food effect using flux- and solubility-based methods., Mol. Pharm., 16, p. 4121, DOI: 10.1021/acs.molpharmaceut.9b00406 6 10.1021/acs.molpharmaceut.9b00406 false true Reference 52453186 /api/reference/52453186 7. Brar 2004: Disulfiram inhibits activating transcription factor/cyclic AMP-responsive element binding protein and human melanoma growth in a metal-dependent manner in vitro, in mice and in a patient with metastatic disease., Mol. Cancer Ther., 3, p. 1049, DOI: 10.1158/1535-7163.1049.3.9 7 10.1158/1535-7163.1049.3.9 false true Reference 52453187 /api/reference/52453187 8. Brewster 2007: Cyclodextrins as pharmaceutical solubilizers., Adv. Drug Deliv. Rev., 59, p. 645, DOI: 10.1016/j.addr.2007.05.012 8 10.1016/j.addr.2007.05.012 false true Reference 52453188 /api/reference/52453188 9. Cannavò 2019: The role of oxidative stress in the biology of melanoma: A systematic review., Pathology - Research and Practice, 215, p. 21, DOI: 10.1016/j.prp.2018.11.020 9 10.1016/j.prp.2018.11.020 false true Reference 52453189 /api/reference/52453189 10. Cen 2004: Disulfiram facilitates intracellular Cu uptake and induces apoptosis in human melanoma cells., J. Med. Chem., 47, p. 6914, DOI: 10.1021/jm049568z 10 10.1021/jm049568z false true Reference 52453190 /api/reference/52453190 11. Cheng 2013: IDH1 mutation is associated with improved overall survival in patients with glioblastoma: a meta-analysis., Tumor Biol., 34, p. 3555, DOI: 10.1007/s13277-013-0934-5 11 10.1007/s13277-013-0934-5 false true Reference 52453191 /api/reference/52453191 12. Dankó 2021: Rapamycin plus doxycycline combination affects growth arrest and selective autophagy-dependent cell death in breast cancer cells., Int. J. Mol. Sci., 22, DOI: 10.3390/ijms22158019 12 10.3390/ijms22158019 false true Reference 52453192 /api/reference/52453192 13. Dhiman 2020: Pharmaceutical applications of cyclodextrins and their derivatives., J. Incl. Phenom. Macrocycl. Chem., 98, p. 171, DOI: 10.1007/s10847-020-01029-3 13 10.1007/s10847-020-01029-3 false true Reference 52453193 /api/reference/52453193 14. Emanuelli 2022: The double-edged sword of oxidative stress in skin damage and melanoma: From physiopathology to therapeutical approaches., Antioxidants (Basel), 11 14 false true Reference 52453194 /api/reference/52453194 15. Farooq 2019: Recent advances in the delivery of disulfiram: a critical analysis of promising approaches to improve its pharmacokinetic profile and anticancer efficacy., DARU J. Pharmaceut. Sci., 27, p. 853, DOI: 10.1007/s40199-019-00308-w 15 10.1007/s40199-019-00308-w false true Reference 52453195 /api/reference/52453195 16. Gampa 2017: Drug delivery to melanoma brain metastases: Can current challenges lead to new opportunities?., Pharmacol. Res., 123, p. 10, DOI: 10.1016/j.phrs.2017.06.008 16 10.1016/j.phrs.2017.06.008 false true Reference 52453196 /api/reference/52453196 17. Gessner, P.K., Gessner, T., 1992. Introduction and scope of monograph. In: Gessner, P.K., Gessner, T. (Eds.), Disulfiram and its metabolite, diethyldithiocarbamate: pharmacology and status in the treatment of alcoholism, HIV infections, AIDS and heavy metal toxicity (pp. 1-6). Springer Netherlands. doi: 10.1007/978-94-011-2328-0_1., DOI: 10.1007/978-94-011-2328-0_1 17 10.1007/978-94-011-2328-0_1 false true Reference 52453197 /api/reference/52453197 18. Halatsch, M.E., Kast, R.E., Karpel-Massler, G., Mayer, B., Zolk, O., Schmitz, B., Scheuerle, A., Maier, L., Bullinger, L., Mayer-Steinacker, R., Schmidt, C., Zeiler, K., Elshaer, Z., Panther, P., Schmelzle, B., Hallmen, A., Dwucet, A., Siegelin, M. D., Westhoff, M.A., Heiland, T., 2021. A phase Ib/IIa trial of 9 repurposed drugs combined with temozolomide for the treatment of recurrent glioblastoma: CUSP9v3. Neuro-Oncol. Adv. 3(1), vdab075, Article vdab075. doi: 10.1093/noajnl/vdab075., DOI: 10.1093/noajnl/vdab075 18 10.1093/noajnl/vdab075 false true Reference 52453198 /api/reference/52453198 19. Hetényi 2002: Efficient docking of peptides to proteins without prior knowledge of the binding site., Protein Sci., 11, p. 1729, DOI: 10.1110/ps.0202302 19 10.1110/ps.0202302 false true Reference 52453199 /api/reference/52453199 20. Higuchi, T., Connor, K.A., 1965. Phase solubility techniques (New York). 20 false true Reference 52453200 /api/reference/52453200 21. Hua 2022: Drug repositioning: progress and challenges in drug discovery for various diseases., Eur. J. Med. Chem., 234, DOI: 10.1016/j.ejmech.2022.114239 21 10.1016/j.ejmech.2022.114239 false true Reference 52453201 /api/reference/52453201 22. Huang 2016: A phase I study to repurpose disulfiram in combination with temozolomide to treat newly diagnosed glioblastoma after chemoradiotherapy., J. Neurooncol, 128, p. 259, DOI: 10.1007/s11060-016-2104-2 22 10.1007/s11060-016-2104-2 false true Reference 52453202 /api/reference/52453202 23. Huang 2018: Final results of a phase I dose-escalation, dose-expansion study of adding disulfiram with or without copper to adjuvant temozolomide for newly diagnosed glioblastoma., J. Neurooncol, 138, p. 105, DOI: 10.1007/s11060-018-2775-y 23 10.1007/s11060-018-2775-y false true Reference 52453203 /api/reference/52453203 24. Huang 2019: A multicenter phase II study of temozolomide plus disulfiram and copper for recurrent temozolomide-resistant glioblastoma., J. Neurooncol, 142, p. 537, DOI: 10.1007/s11060-019-03125-y 24 10.1007/s11060-019-03125-y false true Reference 52453204 /api/reference/52453204 25. Hujber 2018: GABA, glutamine, glutamate oxidation and succinic semialdehyde dehydrogenase expression in human gliomas., J. Exp. Clin. Can. Res., 37, p. 271, DOI: 10.1186/s13046-018-0946-5 25 10.1186/s13046-018-0946-5 false true Reference 52453205 /api/reference/52453205 26. Ichimura 2009: IDH1 mutations are present in the majority of common adult gliomas but rare in primary glioblastomas., Neuro Oncol., 11, p. 341, DOI: 10.1215/15228517-2009-025 26 10.1215/15228517-2009-025 false true Reference 52453206 /api/reference/52453206 27. Ikebukuro 2023: Disulfiram ophthalmic solution inhibited macrophage infiltration by suppressing macrophage pseudopodia formation in a rat corneal alkali burn model., Int. J. Mol. Sci., 24, DOI: 10.3390/ijms24010735 27 10.3390/ijms24010735 false true Reference 52453207 /api/reference/52453207 28. Jacqueline, M., Carreño, S., Guillermo Von Plessing, C., Edson, R., Montero Cabrera F., 2008. Universidad De Concepcion, Laboratorios Andromaco S.A., Abl Pharma Colombia S.A. WO2009083793A1. 28 false true Reference 52453208 /api/reference/52453208 29. Jambhekar 2016: Cyclodextrins in pharmaceutical formulations I: structure and physicochemical properties, formation of complexes, and types of complex., Drug Discov. Today, 21, p. 356, DOI: 10.1016/j.drudis.2015.11.017 29 10.1016/j.drudis.2015.11.017 false true Reference 52453209 /api/reference/52453209 30. Jambhekar 2016: Cyclodextrins in pharmaceutical formulations II: solubilization, binding constant, and complexation efficiency., Drug Discov. Today, 21, p. 363, DOI: 10.1016/j.drudis.2015.11.016 30 10.1016/j.drudis.2015.11.016 false true Reference 52453210 /api/reference/52453210 31. Jullian 2008: Characterization, phase-solubility, and molecular modeling of inclusion complex of 5-nitroindazole derivative with cyclodextrins., Bioorg. Med. Chem., 16, p. 5078, DOI: 10.1016/j.bmc.2008.03.026 31 10.1016/j.bmc.2008.03.026 false true Reference 52453211 /api/reference/52453211 32. Kádár 2022: Flux-based formulation development—a proof of concept study., AAPS J., 24, p. 22, DOI: 10.1208/s12248-021-00668-9 32 10.1208/s12248-021-00668-9 false true Reference 52453212 /api/reference/52453212 33. Kang 2002: SERS of dithiocarbamate pesticides adsorbed on silver surface; Thiram., Bull. Kor. Chem. Soc., 23, p. 1604, DOI: 10.5012/bkcs.2002.23.11.1604 33 10.5012/bkcs.2002.23.11.1604 false true Reference 52453213 /api/reference/52453213 34. Kannappan 2021: Recent advances in repurposing disulfiram and disulfiram derivatives as copper-dependent anticancer agents., Front. Mol. Biosci., 8, DOI: 10.3389/fmolb.2021.741316 34 10.3389/fmolb.2021.741316 false true Reference 52453214 /api/reference/52453214 35. Kaya 2024: Preparation and characterisation of zinc diethyldithiocarbamate-cyclodextrin inclusion complexes for potential lung cancer treatment., Pharmaceutics, 16, p. 65, DOI: 10.3390/pharmaceutics16010065 35 10.3390/pharmaceutics16010065 false true Reference 52453215 /api/reference/52453215 36. Kelley 2021: A Phase 1 dose-escalation study of disulfiram and copper gluconate in patients with advanced solid tumors involving the liver using S-glutathionylation as a biomarker., BMC Cancer, 21, p. 510, DOI: 10.1186/s12885-021-08242-4 36 10.1186/s12885-021-08242-4 false true Reference 52453216 /api/reference/52453216 37. Lanz 2023: Disulfiram: mechanisms, applications, and challenges., Antibiotics, 12, DOI: 10.3390/antibiotics12030524 37 10.3390/antibiotics12030524 false true Reference 52453217 /api/reference/52453217 38. Loftsson 2012: Drug permeation through biomembranes: cyclodextrins and the unstirred water layer., Die Pharmazie - An Int. J. Pharmaceut. Sci., 67, p. 363 38 false true Reference 52453218 /api/reference/52453218 39. Loftsson 2005: Evaluation of cyclodextrin solubilization of drugs., Int. J. Pharm., 302, p. 18, DOI: 10.1016/j.ijpharm.2005.05.042 39 10.1016/j.ijpharm.2005.05.042 false true Reference 52453219 /api/reference/52453219 40. Lopes 2022: Melanoma management: From epidemiology to treatment and latest advances., Cancers, 14, DOI: 10.3390/cancers14194652 40 10.3390/cancers14194652 false true Reference 52453220 /api/reference/52453220 41. Lu 2021: Disulfiram: a novel repurposed drug for cancer therapy., Can. Chemother. Pharmacol., 87, p. 159, DOI: 10.1007/s00280-020-04216-8 41 10.1007/s00280-020-04216-8 false true Reference 52453221 /api/reference/52453221 42. Lu 2022: Leveraging disulfiram to treat cancer: Mechanisms of action, delivery strategies, and treatment regimens., Biomaterials, 281, DOI: 10.1016/j.biomaterials.2021.121335 42 10.1016/j.biomaterials.2021.121335 false true Reference 52453222 /api/reference/52453222 43. Mego, M., Svetlovska, D., Angelis V, D., Kalavska, K., Lesko, P., Makovník, M., Obertova, J., Orszaghova, Z., Palacka, P., Rečková, M., Rejlekova, K., Z, S.-M., Mardiak, J., Chovanec, M., 2022. Phase II study of disulfiram and cisplatin in refractory germ cell tumors. The GCT-SK-006 phase II trial. Investigational New Drugs, 40(5), 1080-1086. doi: 10.1007/s10637-022-01271-1., DOI: 10.1007/s10637-022-01271-1 43 10.1007/s10637-022-01271-1 false true Reference 52453223 /api/reference/52453223 44. Meraz-Torres 2020: Disulfiram as a therapeutic agent for metastatic malignant melanoma—Old myth or new logos?., Cancers, 12, DOI: 10.3390/cancers12123538 44 10.3390/cancers12123538 false true Reference 52453224 /api/reference/52453224 45. Mohammad 2014: Cholesterol depletion by methyl-β-cyclodextrin augments tamoxifen induced cell death by enhancing its uptake in melanoma., Mol. Can., 13, p. 204, DOI: 10.1186/1476-4598-13-204 45 10.1186/1476-4598-13-204 false true Reference 52453225 /api/reference/52453225 46. Morrison 2010: Disulfiram induces copper-dependent stimulation of reactive oxygen species and activation of the extrinsic apoptotic pathway in melanoma., Melanoma Res., 20, DOI: 10.1097/CMR.0b013e328334131d 46 10.1097/CMR.0b013e328334131d false true Reference 52453226 /api/reference/52453226 47. Murk 2022: Forced but effective partners in crime: how astrocytes drive the progression of glioblastoma., Brain, 145, p. 2952, DOI: 10.1093/brain/awac302 47 10.1093/brain/awac302 false true Reference 52453227 /api/reference/52453227 48. Nasrollahzadeh 2021: Anti-proliferative activity of disulfiram through regulation of the AKT-FOXO axis: A proteomic study of molecular targets. Biochimica et Biophysica Acta (BBA) - Molecular., Cell Res., 1868 48 false true Reference 52453228 /api/reference/52453228 49. Nechushtan 2015: A phase IIb trial assessing the addition of disulfiram to chemotherapy for the treatment of metastatic non-small cell lung cancer., Oncologist, 20, p. 366, DOI: 10.1634/theoncologist.2014-0424 49 10.1634/theoncologist.2014-0424 false true Reference 52453229 /api/reference/52453229 50. Okamatsu 2013: Folate-appended β-cyclodextrin as a promising tumor targeting carrier for antitumor drugs in vitro and in vivo., Bioconjug. Chem., 24, p. 724, DOI: 10.1021/bc400015r 50 10.1021/bc400015r false true Reference 52453230 /api/reference/52453230 51. Pereira 2022: Preparation and characterization of disulfiram and beta cyclodextrin inclusion complexes for potential application in the treatment of SARS-CoV-2 via nebulization., Molecules, 27, p. 5600, DOI: 10.3390/molecules27175600 51 10.3390/molecules27175600 false true Reference 52453231 /api/reference/52453231 52. Potula 2020: Repurposing disulfiram (tetraethylthiuram disulfide) as a potential drug candidate against Borrelia burgdorferi in vitro and in vivo., Antibiotics (basel), 9 52 false true Reference 52453232 /api/reference/52453232 53. Pu 2021: Two-dimensional self-assembled Au-Ag core-shell nanorods nanoarray for sensitive detection of thiram in apple using surface-enhanced Raman spectroscopy., Food Chem., 343, DOI: 10.1016/j.foodchem.2020.128548 53 10.1016/j.foodchem.2020.128548 false true Reference 52453233 /api/reference/52453233 54. Puskás 2023: Recent list of cyclodextrin-containing drug products., Period. Polytech., Chem. Eng., 67, p. 11, DOI: 10.3311/PPch.21222 54 10.3311/PPch.21222 false true Reference 52453234 /api/reference/52453234 55. Qu 2021: Therapeutic effect of disulfiram inclusion complex embedded in hydroxypropyl-β-cyclodextrin on intracranial glioma-bearing male rats via intranasal route., Eur. J. Pharm. Sci., 156, DOI: 10.1016/j.ejps.2020.105590 55 10.1016/j.ejps.2020.105590 false true Reference 52453235 /api/reference/52453235 56. Ramachandran 2021: Role of permeability on the biopredictive dissolution of amorphous solid dispersions., AAPS PharmSciTech, 22, p. 243, DOI: 10.1208/s12249-021-02125-4 56 10.1208/s12249-021-02125-4 false true Reference 52453236 /api/reference/52453236 57. Ramadhani 2014: Preparation and characterisation of Kolliphor® P 188 and P 237 solid dispersion oral tablets containing the poorly water soluble drug disulfiram., Int. J. Pharm., 475, p. 514, DOI: 10.1016/j.ijpharm.2014.09.013 57 10.1016/j.ijpharm.2014.09.013 false true Reference 52453237 /api/reference/52453237 58. Said Suliman 2021: Cyclodextrin diethyldithiocarbamate copper II inclusion complexes: A promising chemotherapeutic delivery system against chemoresistant triple negative breast cancer cell lines., Pharmaceutics, 13, DOI: 10.3390/pharmaceutics13010084 58 10.3390/pharmaceutics13010084 false true Reference 52453238 /api/reference/52453238 59. Saokham 2018: Solubility of cyclodextrins and drug/cyclodextrin complexes., Molecules, 23, p. 1161, DOI: 10.3390/molecules23051161 59 10.3390/molecules23051161 false true Reference 52453239 /api/reference/52453239 60. Schweizer 2013: A prostate cancer clinical trials consortium trial of disulfiram (D) in men with nonmetastatic recurrent prostate cancer (PCa)., J. Clin. Oncol., 31, p. 219, DOI: 10.1200/jco.2013.31.6_suppl.219 60 10.1200/jco.2013.31.6_suppl.219 false true Reference 52453240 /api/reference/52453240 61. Sid 2021: Solubility enhancement of mefenamic acid by inclusion complex with β-cyclodextrin: in silico modelling, formulation, characterisation, and in vitro studies., J. Enzyme Inhib. Med. Chem., 36, p. 605, DOI: 10.1080/14756366.2020.1869225 61 10.1080/14756366.2020.1869225 false true Reference 52453241 /api/reference/52453241 62. Sravani, A.B., Shenoy K.M., Chandrika, B., Kumar B.H., Kini, S.G., Pai K.S.R., Lewis, S.A., 2023. Curcumin-sulfobutyl-ether beta cyclodextrin inclusion complex: preparation, spectral characterization, molecular modeling, and antimicrobial activity. J. Biomol. Struct. Dyn. 1–16. doi: 10.1080/07391102.2023.2254409., DOI: 10.1080/07391102.2023.2254409 62 10.1080/07391102.2023.2254409 false true Reference 52453242 /api/reference/52453242 63. Sun 2014: Transdermal delivery of the in situ hydrogels of curcumin and its inclusion complexes of hydroxypropyl-β-cyclodextrin for melanoma treatment., Int. J. Pharm., 469, p. 31, DOI: 10.1016/j.ijpharm.2014.04.039 63 10.1016/j.ijpharm.2014.04.039 false true Reference 52453243 /api/reference/52453243 64. Szabó 2021: Inclusion complexation of the anticancer drug pomalidomide with cyclodextrins: fast dissolution and improved solubility., Heliyon, 7, p. e07581, DOI: 10.1016/j.heliyon.2021.e07581 64 10.1016/j.heliyon.2021.e07581 false true Reference 52453244 /api/reference/52453244 65. Szente 2017: Cyclodextrin-lipid complexes: Cavity size matters., Struct. Chem., 28, p. 479, DOI: 10.1007/s11224-016-0884-9 65 10.1007/s11224-016-0884-9 false true Reference 52453245 /api/reference/52453245 66. Thordarson 2011: Determining association constants from titration experiments in supramolecular chemistry., Chem. Soc. Rev., 40, p. 1305, DOI: 10.1039/C0CS00062K 66 10.1039/C0CS00062K false true Reference 52453246 /api/reference/52453246 67. Tóth 2017: Physicochemical characterization and cyclodextrin complexation of the anticancer drug lapatinib., J. Chem., 2017, p. 4537632, DOI: 10.1155/2017/4537632 67 10.1155/2017/4537632 false true Reference 52453247 /api/reference/52453247 68. Trott 2010: AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading., J. Comput. Chem., 31, p. 455, DOI: 10.1002/jcc.21334 68 10.1002/jcc.21334 false true Reference 52453248 /api/reference/52453248 69. Tyukova 2016: Preparation and molecular composition of an inclusion complex of dilsulfiram and hydroxypropyl-β-cyclodextrin., Pharm. Chem. J., 50, p. 38, DOI: 10.1007/s11094-016-1395-0 69 10.1007/s11094-016-1395-0 false true Reference 52453249 /api/reference/52453249 70. Tyukova 2020: Synthesis of a disulfuram inclusion complex with hydroxypropyl-β-cyclodextrin and its effect on cataract development in rats., Pharm. Chem. J., 53, p. 1158, DOI: 10.1007/s11094-020-02140-y 70 10.1007/s11094-020-02140-y false true Reference 52453250 /api/reference/52453250 71. Wang, S., Li, D., Wang, S., Zhang, J., Wu, C., & Ito, Y. (2002, Shenyang Pharmaceutical University) CN1376463A. 71 false true Reference 52453251 /api/reference/52453251 72. Wang 2004: Bioavailability and anticataract effects of a topical ocular drug delivery system containing disulfiram and hydroxypropyl-beta-cyclodextrin on selenite-treated rats., Curr. Eye Res., 29, p. 51, DOI: 10.1080/02713680490513209 72 10.1080/02713680490513209 false true Reference 52453252 /api/reference/52453252 73. Wei 2023: Application of Cyclodextrin for Cancer Immunotherapy., Molecules, 28, DOI: 10.3390/molecules28145610 73 10.3390/molecules28145610 false true Reference 52453253 /api/reference/52453253 74. Werlenius 2023: Effect of disulfiram and copper plus chemotherapy vs chemotherapy alone on survival in patients with recurrent glioblastoma: a randomized clinical trial., JAMA Netw. Open, 6, p. e234149, DOI: 10.1001/jamanetworkopen.2023.4149 74 10.1001/jamanetworkopen.2023.4149 false true Reference 52453254 /api/reference/52453254 75. Wieder 2022: Drug repositioning for cancer in the era of AI, big omics, and real-world data., Crit. Rev. Oncol. Hematol., 175, DOI: 10.1016/j.critrevonc.2022.103730 75 10.1016/j.critrevonc.2022.103730 false true Reference 52453255 /api/reference/52453255 76. Würth 2016: Drug-repositioning opportunities for cancer therapy: novel molecular targets for known compounds., Drug Discov. Today, 21, p. 190, DOI: 10.1016/j.drudis.2015.09.017 76 10.1016/j.drudis.2015.09.017 false true Reference 52453256 /api/reference/52453256 77. Yokoo 2015: 2-hydroxypropyl-β-cyclodextrin acts as a novel anticancer agent., PLoS One, 10, p. e0141946, DOI: 10.1371/journal.pone.0141946 77 10.1371/journal.pone.0141946 false true Reference 52453257 /api/reference/52453257 78. Zhang 2018: Disulfiram thermosensitive in-situ gel based on solid dispersion for cataract., Asian J. Pharm. Sci., 13, p. 527, DOI: 10.1016/j.ajps.2018.02.010 78 10.1016/j.ajps.2018.02.010 false true Reference 52453258 /api/reference/52453258 79. Zhao 2021: Teaching new tricks to old dogs: A review of drug repositioning of disulfiram for cancer nanomedicine., VIEW, 2, p. 20200127, DOI: 10.1002/VIW.20200127 79 10.1002/VIW.20200127 false true Reference 52453259 /api/reference/52453259 80. Zhong 2022: Disulfiram in glioma: Literature review of drug repurposing., Front. Pharmacol., 13, DOI: 10.3389/fphar.2022.933655 80 10.3389/fphar.2022.933655 false true Reference 52453260 /api/reference/52453260 81. Zirjacks 2021: Repurposing disulfiram for targeting of glioblastoma stem cells: an in vitro study., Biomolecules, 11, DOI: 10.3390/biom11111561 81 10.3390/biom11111561 false true /api/publication/34830527 Benkő Beáta-Mária et al. Cyclodextrin encapsulation enabling the anticancer repositioning of disulfiram: Preparation, analytical and in vitro biological characterization of the inclusion complexes. (2024) INTERNATIONAL JOURNAL OF PHARMACEUTICS 0378-5173 1873-3476 657<div class="JournalArticle Publication long-list"> <div class="authors"> <img title="Forrásközlemény" style="float: left" src="/frontend/resources/grid/publication-core-icon.png"> <img title="Idézőközlemény" style="float: left" src="/frontend/resources/grid/publication-citation-icon.png"> <div class="autype autype0"> <span class="author-name" mtid="10080598"><a href="/gui2/?type=authors&mode=browse&sel=10080598" target="_blank">Benkő Beáta-Mária (<span class="authorship-author-name">Benkő Beáta Mária</span> <span class="authorAux-mtmt"> Gyógyszerészet</span>) </a> </span> <span class="author-affil"><span title="Semmelweis Egyetem">SE</span>/<span title="Gyógyszerésztudományi Kar">GYTK</span>/Egyetemi Gyógyszertár Gyógyszerügyi Szervezési Intézet</span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" mtid="10028950"><a href="/gui2/?type=authors&mode=browse&sel=10028950" target="_blank">Tóth Gergő (<span class="authorship-author-name">Tóth Gergő</span> <span class="authorAux-mtmt"> gyógyszerkémia/analitika</span>) </a> </span> <span class="author-affil"><span title="Semmelweis Egyetem">SE</span>/<span title="Gyógyszerésztudományi Kar">GYTK</span>/Gyógyszerészi Kémiai Intézet</span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" mtid="10078438"><a href="/gui2/?type=authors&mode=browse&sel=10078438" target="_blank">Moldvai Dorottya (<span class="authorship-author-name">Moldvai Dorottya</span> <span class="authorAux-mtmt"> Tumorbiológia</span>) </a> </span> <span class="author-affil"><span title="Semmelweis Egyetem">SE</span>/<span title="Általános Orvostudományi Kar">AOK</span>/<span title="Intézet">I</span>/Patológiai és Kísérleti Rákkutató Intézet</span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" mtid="10073811"><a href="/gui2/?type=authors&mode=browse&sel=10073811" target="_blank">Kádár Szabina (<span class="authorship-author-name">Kádár Szabina</span> <span class="authorAux-mtmt"> Gyógyszertechnológia</span>) </a> </span> <span class="author-affil"><span title="Semmelweis Egyetem">SE</span>/<span title="Gyógyszerésztudományi Kar">GYTK</span>/Gyógyszerészi Kémiai Intézet; <span title="Budapesti Műszaki és Gazdaságtudományi Egyetem">BME</span>/<span title="Vegyészmérnöki és Biomérnöki Kar">VBK</span>/Szerves Kémia és Technológia Tanszék</span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" mtid="10062688"><a href="/gui2/?type=authors&mode=browse&sel=10062688" target="_blank">Szabó Edina (<span class="authorship-author-name">Szabó Edina</span> <span class="authorAux-mtmt"> Gyógyszertechnológia</span>) </a> </span> <span class="author-affil"><span title="Budapesti Műszaki és Gazdaságtudományi Egyetem">BME</span>/<span title="Vegyészmérnöki és Biomérnöki Kar">VBK</span>/Szerves Kémia és Technológia Tanszék</span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" >Szabó Zoltán-István </span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" mtid="10012052"><a href="/gui2/?type=authors&mode=browse&sel=10012052" target="_blank">Kraszni Márta (<span class="authorship-author-name">Mazákné Kraszni Márta</span> <span class="authorAux-mtmt"> Analitikai kémia, gyógyszerkémia</span>) </a> </span> <span class="author-affil"><span title="Semmelweis Egyetem">SE</span>/<span title="Gyógyszerésztudományi Kar">GYTK</span>/Gyógyszerészi Kémiai Intézet</span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" mtid="10008597"><a href="/gui2/?type=authors&mode=browse&sel=10008597" target="_blank">Szente Lajos (<span class="authorship-author-name">Szente Lajos</span> <span class="authorAux-mtmt"> Szerves kémia</span>) </a> </span> <span class="author-affil">CycloLab Cyclodextrin Research and Development Laboratory Ltd.</span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" mtid="10040691"><a href="/gui2/?type=authors&mode=browse&sel=10040691" target="_blank">Fiser Béla (<span class="authorship-author-name">Fiser Béla</span> <span class="authorAux-mtmt"> Számítógépes kémia, Anyagtudomány</span>) </a> </span> <span class="author-affil"><span title="Miskolci Egyetem">ME</span>/<span title="Anyag- és Vegyészmérnöki Kar">AVK</span>/Kémiai Intézet; <span title="II. Rákóczi Ferenc Kárpátaljai Magyar Főiskola ">II.RFKMF</span>/Biológia és Kémia Tanszék</span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" mtid="10000745"><a href="/gui2/?type=authors&mode=browse&sel=10000745" target="_blank">Sebestyén Anna (<span class="authorship-author-name">Sebestyén Anna</span> <span class="authorAux-mtmt"> Tumorbiológia</span>) </a> </span> <span class="author-affil"><span title="Semmelweis Egyetem">SE</span>/<span title="Általános Orvostudományi Kar">AOK</span>/<span title="Intézet">I</span>/Patológiai és Kísérleti Rákkutató Intézet</span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" mtid="10002587"><a href="/gui2/?type=authors&mode=browse&sel=10002587" target="_blank">Zelkó Romána ✉ (<span class="authorship-author-name">Zelkó Romána</span> <span class="authorAux-mtmt"> Gyógyszertechnológia</span>) </a> </span> <span class="author-affil"><span title="Semmelweis Egyetem">SE</span>/<span title="Gyógyszerésztudományi Kar">GYTK</span>/Egyetemi Gyógyszertár Gyógyszerügyi Szervezési Intézet</span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" mtid="10035401"><a href="/gui2/?type=authors&mode=browse&sel=10035401" target="_blank">Sebe István (<span class="authorship-author-name">Sebe István</span> <span class="authorAux-mtmt"> Gyógyszertechnológia</span>) </a> </span> <span class="author-affil"><span title="Semmelweis Egyetem">SE</span>/<span title="Gyógyszerésztudományi Kar">GYTK</span>/Egyetemi Gyógyszertár Gyógyszerügyi Szervezési Intézet; Egis Gyógyszergyár Zrt.</span> </div> </div> <div class="title"><a href="/gui2/?mode=browse&params=publication;34830527" target="_blank">Cyclodextrin encapsulation enabling the anticancer repositioning of disulfiram: Preparation, analytical and in vitro biological characterization of the inclusion complexes</a></div> <div> <span class="journal-title">INTERNATIONAL JOURNAL OF PHARMACEUTICS</span> <span class="journal-issn">(<a target="_blank" href="https://portal.issn.org/resource/ISSN/0378-5173">0378-5173</a> <a target="_blank" href="https://portal.issn.org/resource/ISSN/1873-3476">1873-3476</a>)</span>: <span class="journal-volume">657</span> <span class="page"> Paper 124187. 14 p. </span> <span class="year">(2024)</span> </div> <div class="pub-footer"> <span class="language" xmlns="http://www.w3.org/1999/html">Nyelv: Angol | </span> <span class="identifiers"> <span class="id identifier oa_GOLD" title=" Gold "> <a style="color:blue" title="10.1016/j.ijpharm.2024.124187" target="_blank" href="https://doi.org/10.1016/j.ijpharm.2024.124187"> DOI </a> </span> <span class="id identifier oa_none" title="none"> <a style="color:blue" title="001239063800001" target="_blank" href="https://www.webofscience.com/wos/woscc/full-record/001239063800001"> WoS </a> </span> <span class="id identifier oa_GOLD" title=" Gold "> <a style="color:black" title="205320" target="_blank" href="http://real.mtak.hu/205320"> REAL </a> </span> <span class="id identifier oa_none" title="none"> <a style="color:blue" title="85192089867" target="_blank" href="http://www.scopus.com/record/display.url?origin=inward&eid=2-s2.0-85192089867"> Scopus </a> </span> <span class="id identifier oa_none" title="none"> <a style="color:blue" title="38697585" target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=38697585&dopt=Abstract"> PubMed </a> </span> </span> <OnlyViewableByAuthor><div class="ratings"> <div class="journal-subject">Folyóirat szakterülete: Scopus - Pharmaceutical Science&nbsp;&nbsp;&nbsp;SJR indikátor:&nbsp;Q1</div> </div></OnlyViewableByAuthor> <div class="publication-citation" style="margin-left: 0.5cm;"> <span title="Nyilvános idézőközlemények összesen, említések nélkül" class="citingPub-count">Nyilvános idéző összesen: 17</span> | Független: 14 | Függő: 3 | Nem jelölt: 0 | WoS jelölt: 15 | Scopus jelölt:&nbsp;15 | WoS/Scopus jelölt:&nbsp;16 | DOI jelölt:&nbsp;16 </div> <div class="publication-citation"> <a target="_blank" href="/api/publication?cond=citations.related;eq;34830527&sort=publishedYear,desc&sort=title"> Idézett közlemények száma: 11 </a> </div> <div class="mtid"><span class="long-pub-mtid">Közlemény: 34830527</span> | <span class="status-data status-VALIDATED"> Egyeztetett </span> Forrás Idéző | <span class="type-subtype">Folyóiratcikk ( Szakcikk ) </span> | <span class="pub-category">Tudományos</span> | <span class="publication-sourceOfData">kézi felvitel</span> </div> <div class="funder"> (STIA-KFI-2022), Új Nemzeti Kiválóság Program(ÚNKP-23-3-II-SE95) Támogató: Nemzeti Kutatás, Fejlesztés és Innovációs Iroda, Új Nemzeti Kiválóság Program(ÚNKP-23-3-II-BME-88) Támogató: Nemzeti Kutatás, Fejlesztés és Innovációs Iroda, (TKP2021-NVA-14) Támogató: NKFIH, (NKFIH FK 146930) Támogató: NKFIH, (NKFI-K-142799) Támogató: NKFI </div> <div class="lastModified">Utolsó módosítás: 2026.02.11. 12:07 Laczik Cecilia (SE_AOK_1Patológia_Admin5_LC, admin) </div> <pre class="comment" style="margin-top: 0; margin-bottom: 0;"><u>Megjegyzés</u>: Funding Agency and Grant Number: Semmelweis Science and Innovation Fund; New National Excellence Program of the Ministry for Culture and Innovation from National Research, Development and Innovation Fund [UNKP-23-3-II-SE- 95, UNKP-23-3-II-BME-88]; National Research, Development and Innovation Office, Hungary [TKP2021- NVA-14, NKFIH FK 146930, NKFI-K-142799] Funding text: This resear...</pre> </div></div>